Table 3 Proportion of patients with post-diagnosis health services utilization, stratified by alternative bone metastasis measures
Claims Approach 3 | SEER measure | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Full M1 sample | Concurrent BM | No concurrent BM | BM at diagnosis | No BM at diagnosis | ||||||||
N = 2,708 | N = 1,198 | N = 1,510 | N = 1,694 | N = 1,014 | ||||||||
(44.2%) | (55.8%) | (62.6%) | (37.4%) | |||||||||
N | Col% | N | Col% | N | Col% | P-value | N | Col% | N | Col% | P-value | |
Post-diagnosis resource utilization (i.e., till end of follow-up) | ||||||||||||
Bone mineral density (BMD) | 109 | 4.0 | 40 | 3.3 | 69 | 4.6 | 0.11 | 71 | 4.2 | 38 | 3.8 | 0.57 |
Test | ||||||||||||
PSA test | 2,148 | 79.3 | 906 | 75.6 | 1,242 | 82.3 | <0.01 | 1,389 | 82.0 | 759 | 74.9 | <0.01 |
Oncologist visit | 1,681 | 62.1 | 857 | 71.5 | 824 | 54.6 | <0.01 | 1,041 | 61.5 | 640 | 63.1 | 0.39 |
Nuclear medicine specialist | NR | NR | NR | + | NR | - | 0.07 | NR | >0 | NR | 0.0 | 0.01 |
Visit | ||||||||||||
Radiation oncologist visit | 1,066 | 39.4 | 528 | 44.1 | 538 | 35.6 | <0.01 | 687 | 40.6 | 379 | 37.4 | 0.10 |
Bone biopsy | 79 | 2.9 | 62 | 5.2 | 17 | 1.1 | <0.01 | 47 | 2.8 | 32 | 3.2 | 0.57 |
Bone or joint imaging | 2,200 | 81.2 | 1,006 | 84.0 | 1,194 | 79.1 | <0.01 | 1,406 | 83.0 | 794 | 78.3 | <0.01 |
Treatment receipt (Part B) | ||||||||||||
Radiation | 889 | 32.8 | 445 | 37.2 | 444 | 29.4 | <0.01 | 581 | 34.3 | 308 | 30.4 | 0.04 |
External Beam radiation | 839 | 31.0 | 425 | 35.5 | 414 | 27.4 | <0.01 | 553 | 32.6 | 286 | 28.2 | 0.02 |
Therapy | ||||||||||||
Radiopharmaceutical therapy | 91 | 3.4 | 60 | 5.0 | 31 | 2.1 | <0.01 | 72 | 4.3 | 19 | 1.9 | <0.01 |
Bisphosphonates IV | 862 | 31.8 | 494 | 41.2 | 368 | 24.4 | <0.01 | 593 | 35.0 | 269 | 26.5 | <0.01 |
Erythropoietin | 535 | 19.8 | 274 | 22.9 | 261 | 17.3 | <0.01 | 352 | 20.8 | 183 | 18.1 | 0.08 |
Opioids (moderate-severe) | 624 | 23.0 | 248 | 20.7 | 376 | 24.9 | 0.01 | 379 | 22.4 | 245 | 24.2 | 0.28 |
Claims Approach 3 | SEER measure | |||||||||||
Full M1 sample | Concurrent BM | No concurrent BM | BM at diagnosis | No BM at diagnosis | ||||||||
N = 2,708 | N = 1,198 | N = 1,510 | N = 1,694 | N = 1,014 | ||||||||
(44.2%) | (55.8%) | (62.6%) | (37.4%) | |||||||||
N | Col% | N | Col% | N | Col% | P-value | N | Col% | N | Col% | P-value | |
Resource utilization during the 90-day diagnosis period | ||||||||||||
PSA test | 1,629 | 60.2 | 698 | 58.3 | 931 | 61.7 | 0.07 | 1,046 | 61.8 | 583 | 57.5 | 0.03 |
Bone biopsy | 65 | 2.4 | NR | + | NR | - | <0.01 | 42 | 2.5 | 23 | 2.3 | 0.73 |
Bone or joint imaging | 2,009 | 74.2 | 999 | 83.4 | 1,010 | 66.9 | <0.01 | 1,317 | 77.7 | 692 | 68.2 | <0.01 |
Mean | S.D. | Mean | S.D. | Mean | S.D. | p-value | Mean | S.D. | Mean | S.D. | p-value | |
Post-diagnosis resource utilization (i.e., till end of follow-up) | ||||||||||||
Number of BMD tests | 0.04 | 0.21 | 0.03 | 0.19 | 0.05 | 0.22 | 0.09 | 0.04 | 0.22 | 0.04 | 0.19 | 0.39 |
Number of PSA tests | 8.16 | 10.01 | 8.26 | 10.77 | 8.08 | 9.38 | 0.63 | 8.81 | 10.41 | 7.07 | 9.21 | <0.01 |
Number of PSA tests among patients with PSA tests | 10.29 | 10.23 | 10.93 | 11.15 | 9.82 | 9.47 | 0.02 | 10.75 | 10.56 | 9.44 | 9.54 | <0.01 |
Number of bone biopsies | 0.03 | 0.18 | 0.05 | 0.24 | 0.01 | 0.11 | <0.01 | 0.03 | 0.18 | 0.03 | 0.19 | 0.53 |
Number of bone or joint imaging | 1.65 | 1.58 | 1.67 | 1.56 | 1.64 | 1.61 | 0.60 | 1.73 | 1.61 | 1.52 | 1.53 | <0.01 |
Resource utilization during the 90-day diagnosis period | ||||||||||||
Number of PSA tests | 0.89 | 0.92 | 0.92 | 1.01 | 0.86 | 0.84 | 0.07 | 0.92 | 0.94 | 0.83 | 0.89 | 0.01 |
Number of bone biopsies | 0.02 | 0.16 | 0.05 | 0.23 | 0.003 | 0.06 | <0.01 | 0.03 | 0.17 | 0.02 | 0.15 | 0.60 |
Number of bone or joint imaging | 0.76 | 0.47 | 0.86 | 0.42 | 0.68 | 0.49 | <0.01 | 0.79 | 0.44 | 0.70 | 0.49 | <0.01 |